Allurion Technologies, Inc. a prominent player in the fight against obesity, recently made significant developments by completing a successful public offering and achieving impressive preliminary results for the first quarter of 2024. These exciting developments showcase the company’s dedication to its mission and highlight the potential for continued growth and innovation in the battle against obesity.
Public Offering Success
Allurion Technologies recently announced the successful pricing of an underwritten public offering, raising a total of $17.3 million in gross proceeds. The offering involved 14,406,508 shares of the company’s common stock, along with warrants to purchase an equal number of shares. Priced at $1.20 per share, this public offering signifies the confidence and support of investors in Allurion’s vision and potential to contribute to the resolution of obesity-related concerns.
Preliminary Q1 2024 Results
Building on its previous achievements, Allurion Technologies also shared its preliminary, unaudited results for the first quarter of 2024. Management expects revenue in the range of $9.2 million to $9.3 million, reflecting a growth rate of 12% to 13% compared to the previous quarter in 2023. Furthermore, the company experienced a noteworthy 22% increase in procedural volume growth, as estimated by new app usage. These compelling results demonstrate Allurion’s ability to successfully address the growing obesity epidemic and further solidify its position as a leader in the industry.
Appointment of Milena Alberti-Perez
Adding to its achievements, Allurion Technologies recently appointed Milena Alberti-Perez as its newest board member and Audit Committee Chair, effective from March 11, 2024. Alberti-Perez brings a wealth of experience as an operator and board member, and her expertise will undoubtedly contribute to Allurion’s ongoing success. Dr. Shantanu Gaur, the Founder and CEO of Allurion, expressed his confidence in Alberti-Perez’s leadership and highlighted the valuable perspective she brings to the company.
Conclusion:
Allurion Technologies has made significant strides in its mission to combat obesity, as evidenced by its recent successful public offering, encouraging preliminary results for Q1 2024, and the appointment of Milena Alberti-Perez as Audit Committee Chair. These accomplishments underscore Allurion’s commitment to making a positive impact on public health and its potential for continued growth and success in the fight against obesity.
Comments